Astellas loses bid to block Lexiscan generics in US
pharmaphorum
JANUARY 4, 2023
It looks like Astellas has been unsuccessful in its attempt to block Pfizer’s generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the US. The drug was originally developed by CV Therapeutics – bought by Gilead in 2009 – and first launched in the US in 2008.
Let's personalize your content